GlassScriptPhysician profile
David P Samuels
NPI 1942333158
$46,153.84
in general payments reported to CMS, 2019-2025
21 companies · $83.36 in 2025
The $83.36 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $13K · 2021: $11K · 2022: $3,504 · 2023: $3,702 · 2024: $92.86 · 2025: $83.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,375 · Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,375.00 |
| Food and Beverage | $503.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26,912.47 | 2019-2021 | |
| Abbvie INC. | $14,890.62 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $2,308.46 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $594.01 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $215.37 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $197.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $181.36 | 2019-2022 | |
| Axsome Therapeutics, INC. | $143.38 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $131.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.29 | 2019-2020 | |
| Tris Pharma INC | $76.80 | 2020-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $60.95 | 2021-2023 | Qelbree |
| Adlon Therapeutics L.P. | $50.07 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $45.09 | 2019-2020 | |
| Lundbeck LLC | $44.66 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $43.93 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $39.57 | 2019 | |
| Neuronetics, INC. | $34.89 | 2020 | |
| Shire North American Group INC | $26.80 | 2019 | |
| Bausch Health US, LLC | $14.33 | 2019 | |
| Alkermes, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Samuels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.